ASX:BOD Bod Science (BOD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bod Science Stock (ASX:BOD) 30 days 90 days 365 days Advanced Chart Get Bod Science alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$4.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint pain and stiffness, joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia, as well as contract manufacturing services. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.Read More… Receive BOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bod Science and its competitors with MarketBeat's FREE daily newsletter. Email Address BOD Stock News HeadlinesBod Science Limited Announces Change in Company SecretaryMay 5, 2025 | tipranks.comBod Science Limited Advances Corporate Restructuring with Biortica AcquisitionApril 9, 2025 | tipranks.comTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.June 1, 2025 | Altimetry (Ad)Bod Science Limited Extends DOCA Period Amid ASX Compliance DelaysMarch 19, 2025 | tipranks.comBod Science Reports Quarterly Financials Amidst DOCA and Acquisition ProgressJanuary 24, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:BOD CIKN/A Webbodaustralia.com Phone61 2 9199 5018FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.95 million Net Margins-352.17% Pretax MarginN/A Return on Equity286.46% Return on Assets-113.95% Debt Debt-to-Equity Ratio-34.42 Current Ratio0.30 Quick Ratio2.29 Sales & Book Value Annual Sales$3.32 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA($0.03) per share Price / BookN/AMiscellaneous Outstanding Shares177,340,000Free FloatN/AMarket Cap$4.26 million OptionableNot Optionable Beta1.46 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (ASX:BOD) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bod Science Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bod Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.